Enzon Pharmaceuticals (Enzon Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Change In Receivables?

Enzon Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Enzon Pharmaceuticals's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Enzon Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Enzon Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Enzon Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Enzon Pharmaceuticals's liquidation value for the three months ended in Dec. 2023 was $2.82 Mil.

Enzon Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Enzon Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Change In Receivables Chart

Enzon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

7.97

0.97

-0.02

0.03

Enzon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Enzon Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Enzon Pharmaceuticals (OTCPK:ENZN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Enzon Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Enzon Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Enzon Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	47.012	-	44.197	+	0.75 * 0	+	0.5 * 0
=	2.82

Enzon Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

EZ1:Germany

Address

20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016

Website

http://www.enzon.com

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.

Executives

Randolph C Read	director	C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone	director	C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick	director	C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper	other: See explanation of responses	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc	other: See explanation of responses	2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper	other: See explanation of responses	6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc.	other: See Footnote 1	600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp.	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman	10 percent owner, other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn	10 percent owner	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein	officer: VP-Finance and PFO
Jonathan Christodoro	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121